{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Bandi DSR"],"funding":["NCI NIH HHS"],"pubmed_abstract":["<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense, hypoxic and immune-suppressive tumor microenvironment (TME). Integrin αvβ3-expressing cells, including endothelial and cancer-associated fibroblasts (CAFs), contribute to the development of this TME. ProAgio is a novel cytotoxin that targets integrin αvβ3-expressing cells. ProAgio is currently in clinical trials. We have previously shown that the combination of GPH (gemcitabine, paricalcitol, and hydroxychloroquine) influences PDAC TME. Based on the overlapping mechanisms of action, we hypothesized that ProAgio could potentiate effects of GPH and enhance its anti-tumor immunity.<h4>Methods</h4>Patient-derived xenograft (PDX) and orthotopic models of PDAC were used to assess the therapeutic activity and "],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2026.01.15.699725"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12871271"],"repository":["biostudies-literature"],"pubmed_title":["ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment."],"pmcid":["PMC12871271"],"funding_grant_id":["R01 CA294647","P30 CA013148"],"pubmed_authors":["Malla M","El-Rayes BF","Foote J","Sarvesh S","Masood A","Akce M","Kim H","Nagaraju GP","Bae S","Bandi DSR","Yoon KJ","Liu ZR"],"additional_accession":[]},"is_claimable":false,"name":"ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment.","description":"<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense, hypoxic and immune-suppressive tumor microenvironment (TME). Integrin αvβ3-expressing cells, including endothelial and cancer-associated fibroblasts (CAFs), contribute to the development of this TME. ProAgio is a novel cytotoxin that targets integrin αvβ3-expressing cells. ProAgio is currently in clinical trials. We have previously shown that the combination of GPH (gemcitabine, paricalcitol, and hydroxychloroquine) influences PDAC TME. Based on the overlapping mechanisms of action, we hypothesized that ProAgio could potentiate effects of GPH and enhance its anti-tumor immunity.<h4>Methods</h4>Patient-derived xenograft (PDX) and orthotopic models of PDAC were used to assess the therapeutic activity and ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-04T03:19:56.777Z","creation":"2026-07-04T03:11:51.484Z"},"accession":"S-EPMC12871271","cross_references":{"pubmed":["41648362"],"doi":["10.64898/2026.01.15.699725"]}}